We wouldn’t be able to effectively move the needle on sound healthcare policy without the help of our partners. By working with key stakeholders we can maximize our voice, reach and impact.
Our Partnership Initiatives for Change
To defeat serious chronic conditions, we need to do more than supply the right medicine. We partner with patients, healthcare professionals, advocacy organizations, policymakers and others to raise awareness, improve prevention, promote earlier diagnosis and expand access to care.
Diabetes Advocacy Alliance™ (DAA)
Novo Nordisk is a founding member of the DAA, a coalition that represents patient, professional and trade associations, other nonprofit organizations and corporations. The DAA is united in the effort to change the way diabetes is viewed and treated in America. The vision of the DAA is to influence change in the US healthcare system to improve diabetes prevention, detection and care, and to speed the development of pathways to cures for diabetes.
Learn more at diabetesadvocacyalliance.org
Obesity Care Advocacy Network
We are a member of the Obesity Care Advocacy Network (OCAN), and organization focused on uniting and aligning key obesity stakeholders and the community around key obesity-related education, policy and legislative efforts in order to elevate obesity on the national agenda.
Learn more at obesitycareadvocacynetwork.com
Cities Changing Diabetes
Cities Changing Diabetes is a global program created by Novo Nordisk to address the rise of diabetes in urban settings and the vulnerabilities that contribute to it. In the US, Novo Nordisk is working in Houston, Texas with local stakeholders to develop and implement solutions.
Learn more at citieschangingdiabetes.com
ACT For Diabetes
ACT for Diabetes stands for “Achieving Change Together for Diabetes.” We believe that advocacy is essential to achieving policy change and legislation to give diabetes the attention it deserves. We’re all working toward the same goal and that is to help improve the lives of people affected by diabetes and prediabetes, today and in the future. ACT for Diabetes is an advocacy tool to help people do just that.
Learn more at actfordiabetes.com
For more than three decades, Novo Nordisk has been committed to changing hemophilia. In addition to discovering and developing effective medicines, we work with our community partners to improve the lives of people with hemophilia by creating better access to diagnosis and multidisciplinary care.
Learn more at facebook.com/cpih.us